{"id":"NCT00410761","sponsor":"Genzyme, a Sanofi Company","briefTitle":"An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer","officialTitle":"An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMATM) Versus Placebo in Subjects With Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-11-30","primaryCompletion":"2009-07-31","completion":"2024-07-26","firstPosted":"2006-12-13","resultsPosted":"2012-03-26","lastUpdate":"2024-12-31"},"enrollment":437,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Thyroid Cancer"],"interventions":[{"type":"DRUG","name":"ZD6474 (Vandetanib)","otherNames":["ZACTIMAâ„¢","SAR390530"]}],"arms":[{"label":"1","type":"NO_INTERVENTION"},{"label":"2","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to learn how hereditary or sporadic medullary thyroid cancer patients, treated with ZD6474, react to the drug, what happens to ZD6474 in the human body, about the side effects of ZD6474, and if ZD6474 can decrease or prevent the growth of tumors.","primaryOutcome":{"measure":"Progression-Free Survival(PFS)","timeFrame":"RECIST tumour assessments were performed at screening (within 3 weeks before date of randomisation), then once every 12 weeks up to and including discontinuation of blinded study treatment, unless patients had withdrawn consent.","effectByArm":[{"arm":"Vandetanib 300 mg","deltaMin":30.5,"sd":null},{"arm":"Placebo","deltaMin":19.2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":6},"locations":{"siteCount":127,"countries":["United States","Australia","Austria","Belgium","Brazil","Canada","Czechia","Denmark","France","Germany","Hungary","India","Italy","Mexico","Netherlands","Poland","Portugal","Romania","Russia","Serbia","South Korea","Spain","Sweden","Switzerland"]},"refs":{"pmids":["22025146"],"seeAlso":["http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=348&filename=CSR-D4200C00058.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":71,"n":231},"commonTop":["Diarrhoea","Rash","Nausea","Hypertension","Fatigue"]}}